Guidance
Exchange headwind increased to $1B-$1.2B
Guidance · revenue to $78.25B
← 피드로 돌아가기
01
02
03
04
수요
자본지출
HCA
FY2026 Q2
LOWERED
HCA Healthcare, Inc. 실적 발표
Buzzberg 분석
Exchange headwind increased to $1B-$1.2B
HCA reported Q2 2026 results with diluted EPS growth of 11%, but faced significant headwinds from health insurance exchange disenrollment (15% decline in exchange admissions) that largely migrated to uninsured, leading to a $400M EBITDA hit. Management lowered full-year 2026 guidance to reflect higher exchange impact and slower elective surgery volumes, while noting continued demand growth in insured populations and progress on cost resiliency programs. Exchange volume declined 15% with nearly all patients becoming uninsured, causing a $400M EBITDA impact in Q2 (including $75M upward revision from Q1).
Buzzberg 분석 Exchange headwind increased to $1B-$1.2B HCA reported Q2 2026 results with diluted EPS growth of 11%, but faced significant headwinds from health insurance exchange disenrollment (15% decline in exchange admissions) that largely migrated to uninsured, leading to a $400M EBITDA hit. Management lowered full-year 2026 guidance to reflect higher exchange impact and slower elective surgery volumes, while noting continued demand growth in insured populations and progress on cost resiliency programs. Exchange volume declined 15% with nearly all patients becoming uninsured, causing a $400M EBITDA impact in Q2 (including $75M upward revision from Q1). 전체 분석 보기분석 접기
HCA reported Q2 2026 results with diluted EPS growth of 11%, but faced significant headwinds from health insurance exchange disenrollment (15% decline in exchange admissions) that largely migrated to uninsured, leading to a $400M EBITDA hit. Management lowered full-year 2026 guidance to reflect higher exchange impact and slower elective surgery volumes, while noting continued demand growth in insured populations and progress on cost resiliency programs. Exchange volume declined 15% with nearly all patients becoming uninsured, causing a $400M EBITDA impact in Q2 (including $75M upward revision from Q1).
- Elective inpatient surgeries fell 6% year-over-year (vs. 2% last year), attributed to exchange losses and general affordability pressures.
- Medicaid supplemental payment programs provided $400M net benefit in Q2, largely from Florida, but back-half tailwind expected to wane.
- Full-year 2026 guidance lowered: revenue $77-79.5B, adjusted EBITDA $15.4-16.1B (vs. long-term 4-6% growth target).
Revenue
$20.23B
+6% QoQ
EPS
$7.59
+6% QoQ
Gross margin
15.16%
reported
Op margin
15.16%
reported
이번 분기에 달라진 점
Guidance
Revised guidance: EBITDA $15.4B-$16.1B
Guidance · revenue to $78.25B
Capex
$7 billion in capex over three years
Management maintained their stated CapEx range of $5 billion to $5.5 billion for 2026, and noted they have approved more than $7 billion in capital expenditures coming online over the next three years, including new inpatient beds and outpatient facilities to meet expected…
Demand
Three divisions account for 50% of exchange impact
Management's tone was cautious as they revised full-year guidance downward due to a larger-than-expected impact from the expiration of enhanced premium tax credits, though they expressed confidence in demand trends and their resiliency program.
수요 및 자본지출
수주 및 전환
Three divisions account for 50% of exchange impact. Management's tone was cautious as they revised full-year guidance downward due to a larger-than-expected impact from the expiration of enhanced premium tax credits, though they expressed confidence in demand trends and their resiliency program.
투자 및 생산능력
Management maintained their stated CapEx range of $5 billion to $5.5 billion for 2026, and noted they have approved more than $7 billion in capital expenditures coming online over the next three years, including new inpatient beds and outpatient facilities to meet expected demand.
톤 · cautious
Management's tone was cautious as they revised full-year guidance downward due to a larger-than-expected impact from the expiration of enhanced premium tax credits, though they expressed confidence in demand trends and their resiliency program.
향후 가이던스
LoweredGuidance · revenue to $78.25B · was IN LINE last Q
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| Capex | FY2026 | $5B–$5.5B | $5.25B | MAINTAINED |
| EPS | FY2026 | $28.70–$30.50 | $29.60 | LOWERED |
| Op margin | FY2026 | $15.4B–$16.1B | $15.75B | LOWERED |
| Revenue | FY2026 | $77B–$79.5B | $78.25B | LOWERED |
가이던스 신뢰도
1 / 1달성 또는 상회
| 제시 시점 | 지표 | 목표 기간 | 가이던스 | 실제 | 결과 |
|---|---|---|---|---|---|
| FY2025 Q3 | Capex | FY2025 | $5B | $4.9B | Met / beat |